GB0105560D0 - Pharmaceutical formulations - Google Patents

Pharmaceutical formulations

Info

Publication number
GB0105560D0
GB0105560D0 GBGB0105560.7A GB0105560A GB0105560D0 GB 0105560 D0 GB0105560 D0 GB 0105560D0 GB 0105560 A GB0105560 A GB 0105560A GB 0105560 D0 GB0105560 D0 GB 0105560D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical formulations
formulations
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0105560.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB0105560.7A priority Critical patent/GB0105560D0/en
Publication of GB0105560D0 publication Critical patent/GB0105560D0/en
Priority to EP02703715A priority patent/EP1365767A2/en
Priority to PCT/GB2002/000909 priority patent/WO2002069979A2/en
Priority to JP2002569154A priority patent/JP2004529108A/ja
Priority to US10/469,945 priority patent/US20040136918A1/en
Priority to AU2002237400A priority patent/AU2002237400A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0105560.7A 2001-03-07 2001-03-07 Pharmaceutical formulations Ceased GB0105560D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB0105560.7A GB0105560D0 (en) 2001-03-07 2001-03-07 Pharmaceutical formulations
EP02703715A EP1365767A2 (en) 2001-03-07 2002-03-04 Pharmaceutical formulation comprising r-salmeterol and fluticasone propionate
PCT/GB2002/000909 WO2002069979A2 (en) 2001-03-07 2002-03-04 Pharmaceutical formulation comprising r-salmeterol and fluticasone propionate
JP2002569154A JP2004529108A (ja) 2001-03-07 2002-03-04 Ｒ−サルメテロールおよびプロピオン酸フルチカゾンを含んでなる医薬製剤
US10/469,945 US20040136918A1 (en) 2001-03-07 2002-03-04 Pharmaceutical formulations
AU2002237400A AU2002237400A1 (en) 2001-03-07 2002-03-04 Pharmaceutical formulation comprising r-salmeterol and fluticasone propionate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0105560.7A GB0105560D0 (en) 2001-03-07 2001-03-07 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
GB0105560D0 true GB0105560D0 (en) 2001-04-25

Family

ID=9910112

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0105560.7A Ceased GB0105560D0 (en) 2001-03-07 2001-03-07 Pharmaceutical formulations

Country Status (6)

Country Link
US (1) US20040136918A1 (enExample)
EP (1) EP1365767A2 (enExample)
JP (1) JP2004529108A (enExample)
AU (1) AU2002237400A1 (enExample)
GB (1) GB0105560D0 (enExample)
WO (1) WO2002069979A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
AU2004270171A1 (en) * 2003-08-29 2005-03-17 Glaxo Group Limited Pharmaceutical metered dose inhaler and methods relating thereto
KR20070102659A (ko) * 2004-09-09 2007-10-19 씨아이피엘에이 엘티디. 베타작용제의 이성체 및 항-콜린제를 포함하는 약제학적조성물
EP2486942B1 (en) * 2004-11-24 2018-10-10 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US8758816B2 (en) * 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US9119777B2 (en) * 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US8415390B2 (en) * 2008-05-30 2013-04-09 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
TR201000685A2 (tr) * 2010-01-29 2011-08-22 Bi̇lgi̇ç Mahmut Salmeterol ve flutikazon içeren farmasötik preparatlar.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95936A (en) * 1989-10-10 1996-01-19 Glaxo Group Ltd ) R (-) - (- Hydroxy- (A-]]] 6-) 4- Phenylbutoxy (xyl [amino] methyl [-1,3-benzenedimethanol, its preparation and pharmaceutical preparations containing it
US5919827A (en) * 1990-07-11 1999-07-06 Sepracor Inc. Method for treating asthma using optically pure R(-) salmeterol
AP979A (en) * 1995-04-14 2001-06-28 Glaxo Wellcome Inc Metered dose imhaler for salmeterol.
SK284448B6 (sk) * 1995-04-14 2005-04-01 Glaxo Wellcome Inc. Merací dávkovací inhalátor
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US6136294C1 (en) * 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
AU2206801A (en) * 1999-12-24 2001-07-09 Alan Leslie Cripps Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate

Also Published As

Publication number Publication date
JP2004529108A (ja) 2004-09-24
WO2002069979A2 (en) 2002-09-12
EP1365767A2 (en) 2003-12-03
WO2002069979A3 (en) 2003-04-24
AU2002237400A1 (en) 2002-09-19
US20040136918A1 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
GB0319041D0 (en) Pharmaceutical Formulations
HUP0302857A3 (en) Pharmaceutical formulation
IL164519A0 (en) Pharmaceutical formulations
GB0111597D0 (en) Pharmaceutical compositions
GB0118689D0 (en) Pharmaceutical formulation
GB0104534D0 (en) Pharmaceutical combination
PL366432A1 (en) Pharmaceutical formulation
GB0121715D0 (en) Pharmaceutical formulations
GB2380129B (en) Pharmaceutical formulations
GB0124523D0 (en) Pharmaceutical combination
GB0120701D0 (en) Pharmaceutical formulations
GB2392093B (en) Pharmaceutical formulations
GB0103638D0 (en) Pharmaceutical formulations
GB0105560D0 (en) Pharmaceutical formulations
IL161306A0 (en) Pharmaceutical formulation comprising (r)-bicalutamide
GB0104752D0 (en) Pharmaceutical compositions
GB0129270D0 (en) Pharmaceutical combination
GB0129397D0 (en) Pharmaceutical combination
GB2382302B (en) Pharmaceutical compositions
GB0124455D0 (en) Pharmaceutical formulations
GB0129395D0 (en) Pharmaceutical combination
GB0104749D0 (en) Pharmaceutical formulation
GB0115893D0 (en) Formulations
GB0101966D0 (en) Pharmaceutical formulations
GB0118299D0 (en) Pharmaceutical formulations

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)